Milionis H., Barkas F., Ntaios G., Papavasileiou V., Vemmos K., Michel P., Elisaf M. (2016)
Background/purpose A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors alirocumab and evolocumab. We aimed to investigate the ...